drugset
drugset / Trial / NCT07273474

A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body

NCT07273474 ↗

Phase 1 Completed 12 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out how quickly and to what extent BI 3000202 is processed in the body. The purpose of Part A is to find out how 3000202 moves through and exits the body of healthy people. The purpose of Part B is to find out how much BI 3000202 gets into the blood when participants take it as a tablet compared with when they get it as an infusion. Adults between 18 and 55 years of age can take part if the study doctor determines they are healthy. The doctors regularly check participants' health. To assess the study endpoints, the study staff takes blood, urine, and stool samples.

Timeline

Start
2025-12-30
Primary completion
2026-03-05
Completion
2026-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3000202 Unknown — Oral

Indications

No indication recorded.